TALK
NEUTRAL
$5.18
Live
Talkspace, Inc. · NASDAQ
Target $6.15
(+18.7%)
$2.22
52W Range
$5.2
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 21, 2026
Market cap
$865.45M
P/E
129.5
ROE
6.6%
Profit margin
3.4%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
TALK presents a classic growth-vs-value conflict. While the Piotroski F-Score of 4/9 indicates stable financial health and the company has successfully transitioned to profitability with explosive earnings growth (181% YoY), the valuation is disconnected from deterministic baselines. The stock trades at $5.18, significantly exceeding both the Graham Number ($0.79) and Intrinsic Value ($1.18), suggesting a massive growth premium. Strong liquidity (Current Ratio 6.38) offsets the lack of an Altman Z-Score, but bearish insider activity and a weak technical trend temper the bullish growth narrative.
Key Strengths
Strong revenue growth of 29.30% YoY
Successful transition to profitability with 181.10% earnings growth
Exceptional liquidity with a Current Ratio of 6.38
Positive analyst sentiment with a target price of $6.15
Strong 1-year price performance (+100.8%)
Key Risks
Extreme valuation premium (P/E of 129.50)
Significant divergence from Graham Number ($0.79) and Intrinsic Value ($1.18)
Bearish insider sentiment with CTO selling shares
Thin profit margins (3.40%) leaving little room for operational error
Poor recent earnings surprise record (-45.45% average over last 4 quarters)
AI Fair Value Estimate
Based on comprehensive analysis
$1.5
-71.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
20
85
60
65
0
AI Verdict
Speculative Growth
Key drivers: Earnings inflection, Valuation bubble risk, High liquidity
Confidence
80%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (23.55) is much lower than trailing P/E
Watchpoints
- P/E of 129.50 is excessive
- Price is >6x the Graham Number
Future
85/100
Ref Growth rates
Positives
- 29% Revenue growth
- Triple-digit earnings growth
Watchpoints
- Sustainability of growth rates
Past
60/100
Ref Historical trends
Positives
- Successful pivot from losses to profit
Watchpoints
- History of significant earnings misses
Health
65/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio 6.38 indicates zero short-term liquidity risk
- Piotroski F-Score 4/9 is stable
Watchpoints
- Lack of Altman Z-Score data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payout
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$5.18
Analyst Target
$6.15
Upside/Downside
+18.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TALK and closest competitors.
Updated 2026-04-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TALK
Talkspace, Inc.
Primary
|
-47.7% | +547.5% | +100.8% | +86.3% | +0.8% | 0.0% |
|
QDEL
QuidelOrtho Corporation
Peer
|
-89.6% | -86.0% | -49.5% | -54.8% | -25.4% | -8.2% |
|
TBPH
Theravance Biopharma, Inc.
Peer
|
-25.6% | +44.6% | +83.1% | +16.8% | +16.7% | +1.3% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
INMD
InMode Ltd.
Peer
|
-67.3% | -61.5% | -4.0% | -11.4% | +3.0% | -1.9% |
TAL
Talkspace, Inc.
Primary
5Y
-47.7%
3Y
+547.5%
1Y
+100.8%
6M
+86.3%
1M
+0.8%
1W
0.0%
QDE
QuidelOrtho Corporation
Peer
5Y
-89.6%
3Y
-86.0%
1Y
-49.5%
6M
-54.8%
1M
-25.4%
1W
-8.2%
TBP
Theravance Biopharma, Inc.
Peer
5Y
-25.6%
3Y
+44.6%
1Y
+83.1%
6M
+16.8%
1M
+16.7%
1W
+1.3%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
129.5
Forward P/E
23.55
PEG Ratio
N/A
P/B Ratio
7.38
P/S Ratio
3.78
EV/Revenue
3.38
EV/EBITDA
128.23
Market Cap
$865.45M
Profitability
Profit margins and return metrics
Profit Margin
3.4%
Operating Margin
6.08%
Gross Margin
39.82%
ROE
6.65%
ROA
1.44%
Growth
Revenue and earnings growth rates
Revenue Growth
+29.3%
Earnings Growth
+181.1%
Q/Q Revenue Growth
+29.31%
Q/Q Earnings Growth
+292.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
6.38
Strong
Quick Ratio
6.25
Excellent
Cash/Share
$0.55
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
42.7%
Op. Margin
6.1%
Net Margin
7.6%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.15x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
39%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-19
$0.03
2025-10-30
$0.02
+9.1% surprise
2025-08-05
$N/A
-100.0% surprise
Healthcare Sector Comparison
Comparing TALK against 495 companies in the Healthcare sector
(27 bullish, 152 neutral, 316 bearish)
P/E Ratio
129.5
This Stock
vs
84.2
Sector Avg
+53.8%
(Expensive)
Return on Equity (ROE)
6.65%
This Stock
vs
-95.69%
Sector Avg
-106.9%
(Below Avg)
Profit Margin
3.4%
This Stock
vs
-15.8%
Sector Avg
-121.5%
(Weaker)
Revenue Growth
29.3%
This Stock
vs
138.42%
Sector Avg
-78.8%
(Slower)
Current Ratio
6.38
This Stock
vs
4.66
Sector Avg
+37.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TALK
Talkspace, Inc.
|
NEUTRAL | $865.45M | 129.5 | 6.6% | 3.4% | $5.18 | |
|
QDEL
QuidelOrtho Corporation
|
BEARISH | $865.32M | - | -46.1% | -41.5% | $12.71 | Compare |
|
TBPH
Theravance Biopharma, Inc.
|
NEUTRAL | $860.96M | 8.12 | 44.8% | 98.5% | $16.72 | Compare |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
INMD
InMode Ltd.
|
NEUTRAL | $857.24M | 9.46 | 13.5% | 25.3% | $13.53 | Compare |
TALK
Talkspace, Inc.
NEUTRAL
Mkt Cap
$865M
P/E
129.5
ROE
6.6%
Price
$5.18
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | COHEN JON R | Chief Executive Officer | Stock Award | 387,823 | - |
| 2026-03-31 | REILLY JOHN CHARLES | Officer | Stock Award | 92,108 | - |
| 2026-03-31 | MARGOLIN GIL | Chief Technology Officer | Stock Award | 58,174 | - |
| 2026-03-31 | HARRIS IAN JIRO | Chief Financial Officer | Stock Award | 145,434 | - |
| 2026-03-31 | WATSON KATELYN | Officer | Stock Award | 38,783 | - |
| 2026-02-27 | BRAUNSTEIN DOUGLAS L | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 3,757 | - |
| 2026-02-27 | SHACHAR EREZ | Director | Stock Award | 2,684 | - |
| 2026-02-27 | PAWAR MADHU | Director | Stock Award | 2,147 | - |
| 2026-01-30 | COHEN JON R | Chief Executive Officer | Stock Award | 74,695 | - |
| 2026-01-30 | REILLY JOHN CHARLES | Officer | Stock Award | 20,542 | - |
| 2026-01-30 | MARGOLIN GIL | Chief Technology Officer | Stock Award | 49,797 | - |
| 2026-01-30 | HARRIS IAN JIRO | Chief Financial Officer | Stock Award | 49,797 | - |
| 2026-01-30 | WATSON KATELYN | Officer | Stock Award | 22,409 | - |
| 2025-12-11 | MARGOLIN GIL | Chief Technology Officer | Sale | 14,542 | $47,407 |
| 2025-12-02 | MARGOLIN GIL | Chief Technology Officer | Sale | 3,516 | $11,075 |
COHEN JON R
Chief Executive Officer
2026-03-31
387,823 shares
REILLY JOHN CHARLES
Officer
2026-03-31
92,108 shares
MARGOLIN GIL
Chief Technology Officer
2026-03-31
58,174 shares
HARRIS IAN JIRO
Chief Financial Officer
2026-03-31
145,434 shares
WATSON KATELYN
Officer
2026-03-31
38,783 shares
BRAUNSTEIN DOUGLAS L
Director and Beneficial Owner of more than 10% of a Class of Security
2026-02-27
3,757 shares
SHACHAR EREZ
Director
2026-02-27
2,684 shares
PAWAR MADHU
Director
2026-02-27
2,147 shares
COHEN JON R
Chief Executive Officer
2026-01-30
74,695 shares
REILLY JOHN CHARLES
Officer
2026-01-30
20,542 shares
MARGOLIN GIL
Chief Technology Officer
2026-01-30
49,797 shares
HARRIS IAN JIRO
Chief Financial Officer
2026-01-30
49,797 shares
WATSON KATELYN
Officer
2026-01-30
22,409 shares
MARGOLIN GIL
Chief Technology Officer
2025-12-11
14,542 shares
·
$47,407
MARGOLIN GIL
Chief Technology Officer
2025-12-02
3,516 shares
·
$11,075
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
8-K
8-K
8-K
10-Q
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
5 analysts
Barclays
2026-03-10
Equal-Weight
Equal-Weight
Keybanc
2026-03-10
Overweight
Sector Weight
Canaccord Genuity
2026-03-09
Buy
Hold
Needham
2026-03-09
Buy
Hold
TD Cowen
2026-02-20
Buy
Buy
Needham
2026-02-19
Buy
Buy
Keybanc
2026-01-08
Overweight
Overweight
Barclays
2025-12-09
Equal-Weight
Needham
2025-12-02
Buy
Buy
Canaccord Genuity
2025-10-31
Buy
Buy
Past News Coverage
Recent headlines mentioning TALK from our newsroom.
Newest → oldest
No matching news yet.